Literature DB >> 8312688

Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis.

M M Weber1, J Lang, F Abedinpour, K Zeilberger, B Adelmann, D Engelhardt.   

Abstract

The narcotic agent etomidate and the antimycotic drug ketoconazole are known to block steroid biosynthesis in man. To study the different effects of these imidazole derivatives on human adrenal steroid biosynthesis we incubated slices of human adrenal glands with 3H-labeled precursors and increasing concentrations of etomidate or ketoconazole (0-2000 microM). After extraction the labeled metabolites were separated by thin-layer chromatography and quantified by scintillation counting. Etomidate inhibited most potently 11 beta-hydroxylase activity by suppressing the formation of corticosterone from 11-deoxycorticosterone to 1% of control [50% inhibitory concentration (IC50) 0.03 microM] while ketoconazole suppressed 11 beta-hydroxylase to only 39% of control activity (IC50 15 microM). Ketoconazole however, most potently blocked the conversion of 17 alpha-hydroxy-progesterone to androstenedione by C17,20-desmolase to about 15% of control activity (IC50 1 microM) while etomidate showed a much weaker effect on this enzyme with a suppression to 50% of C17,20-desmolase control activity at a concentration of 380 microM. Both imidazole drugs showed a similar strong inhibitory effect on the activity of 17 alpha-hydroxylase (IC50 6-18 microM) and 16 alpha-hydroxylase (IC50 4-8 microM) and did not affect 21-hydroxylase. These in vitro data indicate a predominant inhibitory effect of etomidate on corticosteroid biosynthesis by relative selective inhibition of 11 beta-hydroxylase and of ketoconazole on the adrenal androgen biosynthesis by a predominant inhibition of C17,20-desmolase. This differential inhibitory effect of etomidate and ketoconazole on human steroid biosynthesis may be of clinical importance for a possible therapeutic use of these imidazole derivatives in endocrine disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8312688     DOI: 10.1007/bf00185607

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  29 in total

1.  Effect of ketoconazole, etomidate and other inhibitors of steroidogenesis on cytochrome P-450sccII-catalyzed reactions.

Authors:  K Nagai; I Miyamori; R Takeda; K Suhara; M Katagiri
Journal:  J Steroid Biochem       Date:  1987-09       Impact factor: 4.292

2.  Hormonal and clinical effects of ketoconazole in hirsute women.

Authors:  H Martikainen; J Heikkinen; A Ruokonen; A Kauppila
Journal:  J Clin Endocrinol Metab       Date:  1988-05       Impact factor: 5.958

3.  Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals.

Authors:  H Vanden Bossche; G Willemsens; W Cools; D Bellens
Journal:  Biochem Pharmacol       Date:  1984-12-01       Impact factor: 5.858

4.  Primary adrenocortical micronodular adenomatosis causing Cushing's syndrome. Effects of ketoconazole on steroid production and in vitro performance of adrenal cells.

Authors:  W Oelkers; V Bähr; J Hensen; H Pickartz
Journal:  Acta Endocrinol (Copenh)       Date:  1986-11

5.  Ketoconazole therapy in advanced prostatic cancer.

Authors:  J Trachtenberg
Journal:  J Urol       Date:  1984-07       Impact factor: 7.450

6.  Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole.

Authors:  M Ayub; M J Levell
Journal:  J Steroid Biochem       Date:  1989-04       Impact factor: 4.292

7.  The effect of ketoconazole on steroidogenesis. II. Adrenocortical enzyme activity in vitro.

Authors:  B D Albertson; N C Maronian; K L Frederick; M DiMattina; P Feuillan; J F Dunn; D L Loriaux
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1988-07

8.  Adrenocortical suppression by a single induction dose of etomidate.

Authors:  B Allolio; R Stuttmann; U Leonhard; H Fischer; W Winkelmann
Journal:  Klin Wochenschr       Date:  1984-11-02

9.  Stereoisomers of ketoconazole: preparation and biological activity.

Authors:  D M Rotstein; D J Kertesz; K A Walker; D C Swinney
Journal:  J Med Chem       Date:  1992-07-24       Impact factor: 7.446

10.  Site of action of low dose ketoconazole on androgen biosynthesis in men.

Authors:  R J Santen; H Van den Bossche; J Symoens; J Brugmans; R DeCoster
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

View more
  8 in total

Review 1.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Steroid biosynthesis inhibitors in Cushing's syndrome.

Authors:  D Engelhardt
Journal:  Clin Investig       Date:  1994-07

3.  11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis.

Authors:  Rafal M Kaminski; Michael A Rogawski
Journal:  Neuropharmacology       Date:  2011-03-31       Impact factor: 5.250

Review 4.  Adrenal function and dysfunction in critically ill patients.

Authors:  Arno Téblick; Bram Peeters; Lies Langouche; Greet Van den Berghe
Journal:  Nat Rev Endocrinol       Date:  2019-07       Impact factor: 43.330

5.  Treatment Options in Cushing's Disease.

Authors:  Ahmed Rizk; Juergen Honegger; Monika Milian; Tsambika Psaras
Journal:  Clin Med Insights Oncol       Date:  2012-01-11

Review 6.  Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Authors:  A G Ambrogio; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2016-04-16       Impact factor: 4.256

Review 7.  Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.

Authors:  Iosif A Mendichovszky; Andrew S Powlson; Roido Manavaki; Franklin I Aigbirhio; Heok Cheow; John R Buscombe; Mark Gurnell; Fiona J Gilbert
Journal:  Diagnostics (Basel)       Date:  2016-11-18

Review 8.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.